| Objective: The unidentified gastrointestinal bleeding can’tbe detected clearly by gastroscope, colonoscopy and conventional BeiCancheck, the lesion site located mainly in the small intestine. In recent years,used in clinical double-balloon enteroscopy check for a long time, checkfor intestines convulsion wait for a reason to feel bad, even with pain, youneed to stay calm and analgesic applications, which limits its clinicalvalue. Capsule endoscopy can visible, painless do small intestinalinspection, the inspection results in the digestive tract by capsules insports, Check before the bowel preparation factors. Mossa will the is aselective5-HT4agonists, through the excited gastrointestinal cholinergicneurons and between muscle among plexus5-HT4receptor and promoteacetylcholine release, and strengthen the gastrointestinal movement.Thisexperimental analysis and evaluation of promote gastrointestinal motilitydrug (Mosapride citrate) in the diagnosis of obscure gastrointestinalbleeding disease with OMOM capsule endoscopy. We subject toprovide a theoretical basis for improving the capsule endoscopy in thepreoperative preparation, and promote the application of capsuleendoscopy in clinical diagnosis and effects. Method: total94patientswith obscure gastrointestinal bleeding capsule endoscopy in our hospital from August2008to April2012were randomly divided into group A andB, according to whether have been applied to promoting gastrointestinalmotility drugs, before surgery. Group A (n=64) were as control group,and group B (n=30cases) for the experimental group, are in the capsuleendoscopy before in the same drug clean the intestines.The group Bgiven the mosapride citrate tablets (dose:5mg/adult patients)30minbefore Capsule endoscopy. image quality, patient compliance and safetyof the capsule endoscopy capsule between the two groups. Observepatients to OMOM capsule endoscopy check compliance; Capsuleendoscopy safety; Capsule endoscopy acquisition pictures quality;Analysis passing time in the pylorus，running time in the small intestine，the passing proportion of the ileocecal valve lesion, the positive detection.Results: Group A failure in1check. The patients with capsule endoscopystudies compliance, the security, the image quality were no obviousdifference between the two groups. Group A: stomach through time is59.20±75.21min; the checking time in small intestine is289.66±123.63min. Patients with small bowel examination completionrate were74.6%(47/63), the positive rate of82.5%(52/63). Group B:stomach through time was27.30±23.52min. Check the time in the smallintestine255.37±131.38min. Patients with small bowel examinationcompletion rate were93.3%(28/30). Diagnostic positive rate was93.3%(28/30). Contrast of A and B group, stomach through time capsule endoscopy in group B short in group A (P <0.05), check completion ofthe rate was better than group A (P <0.05). The two groups in terms ofthe running time of capsule endoscopy in the small intestine and thepositive diagnosis rate have no significant difference (P>0.05).Discussion: Taken promote gastrointestinal motility agents (sodiumcitrate mosapride tablets) before capsule endoscopy, can through thepromote gastric peristalsis, to speed up the intelligent capsules in movewithin the stomach, to small intestine as early as possible; and it can alsoimprove the completion rate of small bowel capsule endoscopyexamination;However, the positive rate were different between two groups. Eventhough there were no statistically differences, probably because of thesmall sample size. In addition, taking promote gastrointestinal motilitydrugs before the capsule endoscopy did not lead to increasedcomplications in the checking process. And this is proved its security.Therefore, Application to promote gastrointestinal power drugs beforecapsule endoscopy was helped for diagnosis of obscure gastrointestinalbleeding disease. |
PDF Full Text Request